Literature DB >> 18207355

Claudication distances and the Walking Impairment Questionnaire best describe the ambulatory limitations in patients with symptomatic peripheral arterial disease.

Sara A Myers1, Jason M Johanning, Nick Stergiou, Thomas G Lynch, G Matthew Longo, Iraklis I Pipinos.   

Abstract

BACKGROUND: Claudication secondary to peripheral arterial disease leads to reduced mobility, limited physical functioning, and poor health outcomes. Disease severity can be assessed with quantitative clinical methods and qualitative self-perceived measures of quality of life. Limited data exist to document the degree to which quantitative and qualitative measures correlate. The current study provides data on the relationship between quantitative and qualitative measures of symptomatic peripheral arterial disease.
METHOD: This descriptive case series was set in an academic vascular surgery unit and biomechanics laboratory. The subjects were symptomatic patients with peripheral arterial disease patients presenting with claudication. The quantitative evaluation outcome measures included measurement of ankle-brachial index, initial claudication distance, absolute claudication distance, and self-selected treadmill pace. Qualitative measurements included the Walking Impairment Questionnaire (WIQ) and the Medical Outcomes Study Short Form-36 (SF-36) Health Survey. Spearman rank correlations were performed to determine the relationship between each quantitative and qualitative measure and also between the WIQ and SF-36.
RESULTS: Included were 48 patients (age, 62 +/- 9.6 years; weight, 83.0 +/- 15.4 kg) with claudication (ABI, 0.50 +/- 0.20). Of the four WIQ subscales, the ankle-brachial index correlated with distance (r = 0.29) and speed (r = 0.32); and initial claudication distance and absolute claudication distance correlated with pain (r = 0.40 and 0.43, respectively), distance (r = 0.35 and 0.41, respectively), and speed (r = 0.39 and 0.39 respectively). Of the eight SF-36 subscales, no correlation was found for the ankle-brachial index, initial claudication distance correlated with Bodily Pain (r = 0.46) and Social Functioning (r = 0.30), and absolute claudication time correlated with Physical Function (r = 0.31) and Energy (r = 0.30). The results of both questionnaires showed reduced functional status in claudicating patients.
CONCLUSIONS: Initial and absolute claudication distances and WIQ pain, speed, and distance subscales are the measures that correlated the best with the ambulatory limitation of patients with symptomatic peripheral arterial disease. These results suggest the WIQ is the most specific questionnaire for documenting the qualitative deficits of the patient with claudication while providing strong relationships with the quantitative measures of arterial disease. Future studies of claudication patients should include both quantitative and qualitative assessments to adequately assess disease severity and functional status in peripheral arterial disease patients.

Entities:  

Mesh:

Year:  2008        PMID: 18207355     DOI: 10.1016/j.jvs.2007.10.052

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  24 in total

1.  Abnormal joint powers before and after the onset of claudication symptoms.

Authors:  Panagiotis Koutakis; Jason M Johanning; Gleb R Haynatzki; Sara A Myers; Nicholas Stergiou; G Matthew Longo; Iraklis I Pipinos
Journal:  J Vasc Surg       Date:  2010-08       Impact factor: 4.268

2.  The Effect of Hachimi-Jio-Gan (Ba-Wei-Di-Huang-Wan) on the Quality of Life in Patients with Peripheral Arterial Disease - A Prospective Study Using Kampo Medicine.

Authors:  Koji Kawago; Shunya Shindo; Hidenori Inoue; Junetsu Akasaka; Shinya Motohashi; Go Urabe; Masahiro Sato; Hirotomo Uchiyama; Hitoshi Ogino
Journal:  Ann Vasc Dis       Date:  2016-09-15

3.  Minimal clinically important differences in treadmill, 6-minute walk, and patient-based outcomes following supervised and home-based exercise in peripheral artery disease.

Authors:  Andrew W Gardner; Polly S Montgomery; Ming Wang
Journal:  Vasc Med       Date:  2018-04-19       Impact factor: 3.239

Review 4.  Assessment of functional status and quality of life in claudication.

Authors:  Ryan J Mays; Ivan P Casserly; Wendy M Kohrt; P Michael Ho; William R Hiatt; Mark R Nehler; Judith G Regensteiner
Journal:  J Vasc Surg       Date:  2011-02-18       Impact factor: 4.268

5.  The effects of smoking status on walking ability and health-related quality of life in patients with peripheral arterial disease.

Authors:  Cynthia Fritschi; Eileen G Collins; Susan O'Connell; Conor McBurney; Jolene Butler; Lonnie Edwards
Journal:  J Cardiovasc Nurs       Date:  2013 Jul-Aug       Impact factor: 2.083

6.  The effect of pharmacological treatment on gait biomechanics in peripheral arterial disease patients.

Authors:  Jessie M Huisinga; Iraklis I Pipinos; Jason M Johanning; Nicholas Stergiou
Journal:  J Neuroeng Rehabil       Date:  2010-06-07       Impact factor: 4.262

7.  Effects of the 5-HT2A Antagonist Sarpogrelate on Walking Ability in Patients with Intermittent Claudication as Measured Using the Walking Impairment Questionnaire.

Authors:  Hiroshi Matsuo; Hiroshi Shigematsu
Journal:  Ann Vasc Dis       Date:  2008-09-25

8.  Predictors of health-related quality of life in patients with symptomatic peripheral artery disease.

Authors:  Andrew W Gardner; Polly S Montgomery; Ming Wang; Cong Xu
Journal:  J Vasc Surg       Date:  2018-03-31       Impact factor: 4.268

9.  Walking impairment questionnaire improves mortality risk prediction models in a high-risk cohort independent of peripheral arterial disease status.

Authors:  Kevin T Nead; Margaret Zhou; Roxanne Diaz Caceres; Jeffrey W Olin; John P Cooke; Nicholas J Leeper
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2013-04-30

10.  Functional claudication distance: a reliable and valid measurement to assess functional limitation in patients with intermittent claudication.

Authors:  Lotte M Kruidenier; Saskia P A Nicolaï; Edith M Willigendael; Rob A de Bie; Martin H Prins; Joep A W Teijink
Journal:  BMC Cardiovasc Disord       Date:  2009-03-02       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.